|
MechanismPCSK9 inhibitors |
|
|
|
|
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Blank Controlled, Multicenter Clinical Trial of the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence
Assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis formation or recurrence.
100 Clinical Results associated with DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
0 Patents (Medical) associated with DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
100 Deals associated with DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
100 Translational Medicine associated with DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED